Blue Cap AG (B7E) Fair Value & Analysis
Financial Services · DE · Market cap €86.4M
Fair value as of: Jun 26, 2026
Analysis
Blue Cap AG (B7E) currently trades at €17.85, while our model-based Fair Value estimate is €34.58 — implying the stock looks roughly 93.7% undervalued today. We read business quality at 92/100 (high quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Blue Cap AG is a private equity firm based in Munich, Germany, specializing in investments in middle market, late-stage, mature, turnaround, recapitalization, buyout, special situations, restructuring, corporate carve-outs, and growth capital. It focuses on SMEs, particularly B2B companies in industrial goods and services across sectors such as adhesives & coatings, plastics, business services, and medical. The firm targets investments in Germany, Austria, and Switzerland, typically ranging from $5.65 million to $28.3 million in equity, with target sales between "20 million ($23.46 million) and "200 million ($234.65 million), and EBITDA up to $10 million. Blue Cap prefers majority stakes and aims for exits within three to seven years, investing from its balance sheet capital. Founded in 2006, the firm operates with a long-term, value-driven approach.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Blue Cap AG (B7E) undervalued?
What is the fair value of B7E?
What is the quality score of B7E?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.